Abstract

Human LAR is a transmembrane receptor-like protein whose cytoplasmic region contains two tandemly duplicated domains homologous to protein tyrosine phosphatases (PTPases). Whereas the membrane-proximal domain I has enzymatic activity, the membrane-distal domain II has no apparent catalytic activity but seems to have a regulatory function. In order to study structure-function relationships of the LAR PTPase, LAR domain I was expressed in Escherichia coli, and mutants that have reduced catalytic activity or reduced thermostability were isolated and characterized. We isolated 18 unique hydroxylamine-induced missense mutations in the LAR domain I segment, of which three were temperature-sensitive. Five additional temperature-sensitive mutations were isolated using N-methyl-N'-nitro-N-nitrosoguanidine. All eight temperature-sensitive mutations are confined within a short segment of the LAR domain I sequence between amino acid positions 1329 and 1407. To examine whether this region is particularly prone to temperature-sensitive mutations, tyrosine at amino acid position 1379 was changed to a phenylalanine by oligonucleotide-directed mutagenesis. This mutant, Y1379-F, was indeed temperature-sensitive. We also isolated a revertant of a temperature-sensitive mutant. The revertant contained a second-site mutation (C1446-Y) that suppresses several temperature-sensitive mutations and also enhances the folding of LAR protein produced in E. coli.

Highlights

  • We reportedan same holds true for the LAR-Dl PTPase, thencltuhsetering analysis of the LAR PTPase using site-directed mutagenesis of the ts mutations might be an indication that thesegment

  • (15).We described the isolation and initial characteriza- is buried within thefolded tion of chemically induced LARmutants

  • LAR-Dl mutations inducible by hydroxylamine, indicating PTPase itself was slightlystabler than thwe ild-type enzyme

Read more

Summary

RESULTS

Nomenclature of Mutations-Each mutation was sequencially numbered and has a prefix indicating the mutagen used (HA for ization of LAR-Dl mutants,we used a plasmid that expresses only the domain I of the LAR PTPase, i.e. pKKUCLAR.A(l614-1881) (15). In this paper, this plasmid willbe referred to as pKKUC-LAR-DlF. Purified, supercoiled pKKUC-LAR-Dl plasmid DNA the overproduction of LAR-Dl PTPase, thesegment of human LAR cDNA encoding the amino acid positions 1275 through 1613 was modified so that thissequence is flanked by a BamHI site at the 5' end and a termination codon and a HindIII site at the 3' end.

A Ig-like domains
AII mutations
I Ill I ll I J
A LAR-Dl LAR-Dl
B LAR-Dl LAR-Dl
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call